TMTatum van Maanen

Tatum van Maanen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tatum van Maanen has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Antonios Daletzakis

    Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands

    1 shared publication
  • Britt B. M. Suelmann

    Department of Medical Oncology, University Medical Center of Groningen, University of Groningen, Groningen, The Netherlands

    1 shared publication
  • Cheryl P. Bruijnen

    Department of Medical Oncology, University Medical Center of Utrecht, University of Utrecht, Utrecht, The Netherlands

    1 shared publication
  • Cindy M. J. Hollander

    Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands

    1 shared publication
  • Daniel J. Vis

    Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands

    1 shared publication
  • Hamza Ali

    Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial

    by Sarah M. H. Einerhand, Hamza Ali, Stephen Q. Wong, Jeroen van Dorp, Tatum van Maanen, Jeantine M. de Feijter, Maurits L. van Montfoort, Thierry N. Boellaard, Linde M. Braaf, Wim Brugman, et al.

    New therapeutic strategies for patients with therapy-refractory metastatic urothelial carcinoma (mUC) are still needed. In the phase I-II ICRA trial, a multicenter, open-label, phase Ib-II clinical trial (NCT03871036), we evaluated whether paclitaxel plus tremelimumab, with or without durvalumab, could induce a tumor response in mUC following platinum chemotherapy and immune checkpoint inhibition (ICI). Patients were randomized between three arms: A (n = 20) paclitaxel plus T750mg; B (n = 12) paclitaxel plus T300mg plus D1500mg; C (n = 12) T750mg. The primary outcome, objective response rate, was met with 26% in arm A (88% CI = [14,36%]) versus 17% (88% CI = [3,42%]) in arm B and 8% (88% CI = [0.3,33%]) in arm C. Secondary outcomes included safety, duration of response and survival. Grade 3-4 treatment-related adverse events occurred in (A) 45%, (B) 75%, and (C) 25% of patients. Murine experiments showed attenuated tumor outgrowth for paclitaxel plus anti-CTLA-4 compared to monotherapy with either agent. Transcriptomic analyses showed upregulation of inflammation signatures in on-treatment tumor tissue biopsies. This study demonstrated encouraging antitumor activity in therapy-refractory mUC treated with paclitaxel plus high-dose anti-CTLA-4 and suggests immune induction may still be possible after failure to anti-PD-(L)1 therapy.